Competition from generics are hurting Zoloft, Norvasc and Lipitor sales. Torcetrapib was supposed to save them – but now the pipeline looks pretty empty.
Related Stories
More in Uncategorized
Comments
- Vijay Goel, M.D.
- Anonymous
Previous post: From India
Next post: "This is not a bill"




